Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
暂无分享,去创建一个
R. Gray | T. Powles | C. Wilson | I. Holen | M. Gnant | R. Gray | M. Aapro | N. Harbeck | B. Thürlimann | M. Untch | D. Cameron | D. Dodwell | I. Smith | C. Markopoulos | D. Dodwell | J. Bergh | A. Leo | J. Body | M. Kaufmann | M. Martín | P. Conte | Miguel Martín | A. Di Leo | B. Ejlertsen | R. Coleman | P. Clézardin | D. Santini | I. Diel | U. Albert | Caroline Wilson | J. Cortés | P. Hadji | L. Costa | B. Thurlimann | L. Costa | M. Kaufmann | J. Bergh | M. Martín | J. Cortes
[1] C. Löwik,et al. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. , 2009, Bone.
[2] P. Clézardin,et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. , 2007, Journal of the National Cancer Institute.
[3] Ivo Que,et al. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. , 2005, Cancer research.
[4] H. Sommer,et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. , 2010, Anticancer research.
[5] I. Holen,et al. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. , 2014, Endocrine-related cancer.
[6] D. Dodwell,et al. Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer , 2008, Clinical Cancer Research.
[7] G. Hortobagyi,et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. , 2015 .
[8] Janet E Brown,et al. Management of cancer treatment-induced bone loss , 2013, Nature Reviews Rheumatology.
[9] E. Perez,et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Schneeweiss,et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Ellis,et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. , 2010, The Lancet. Oncology.
[12] P. Neven,et al. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. , 2012, Clinical breast cancer.
[13] C. Wilson,et al. Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates. , 2012, Cancer treatment reviews.
[14] P. Musiani,et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway , 2009, Journal of cellular and molecular medicine.
[15] E. Winer,et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. , 2011, European journal of cancer.
[16] H. Brenner,et al. Meta-analysis: serum vitamin D and breast cancer risk. , 2010, European journal of cancer.
[17] N. Mayo,et al. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study. , 2014, Journal of the National Cancer Institute.
[18] H. Kato,et al. The role of bisphosphonates and bone health issues in Japanese Breast Cancer patients: Efficacy of alendronate with aromatase inhibitors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Cauley,et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] T. Powles,et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Giobbie-Hurder,et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. , 2009, The New England journal of medicine.
[22] E. Abt,et al. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review , 2011, Nature Reviews Endocrinology.
[23] C. Blomqvist,et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Greil,et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial , 2015, The Lancet.
[25] M. Rogers,et al. Molecular Mechanisms of Action of Bisphosphonates: Current Status , 2006, Clinical Cancer Research.
[26] J. Cuzick,et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial , 2014, The Lancet.
[27] L. Suva,et al. Bone turnover across the menopause transition , 2010, Annals of the New York Academy of Sciences.
[28] E. Perez,et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. , 2012, The Lancet. Oncology.
[29] W. Sauerbrei,et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) , 2003, Osteoporosis International.
[30] F. Schuetz,et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] M. Aapro,et al. Bone health in cancer patients: ESMO Clinical Practice Guidelines. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] S. Silverman,et al. The Utility and Limitations of FRAX: A US Perspective , 2010, Current osteoporosis reports.
[33] J. Mackey,et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] C. Wilson,et al. Adjuvant therapy with bone-targeted agents , 2011, Current opinion in supportive and palliative care.
[35] R. Eastell,et al. Long-term effects of aromatase inhibitors on bone , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[36] K. Berg,et al. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial , 2010, Osteoporosis International.
[37] A. Howell,et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. , 2008, Cancer treatment reviews.
[38] J. Forbes,et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] T. Powles,et al. Correction: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] , 2006, Breast Cancer Research.
[40] L. Rutqvist,et al. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] J. Bergh,et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer , 2008, Acta oncologica.
[42] I. Holen,et al. Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment In Vivo , 2014, Clinical Cancer Research.
[43] R. Greil,et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. , 2008, The Lancet. Oncology.
[44] J. Mönkkönen,et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. , 2011, Cancer research.
[45] I. Holen,et al. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer , 2010, Breast Cancer Research.
[46] P. Neven,et al. Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole , 2008, Cancer.
[47] R. Greil,et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[48] R. Aft,et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. , 2013, The oncologist.
[49] I. Holen,et al. Modifying the osteoblastic niche with zoledronic acid in vivo—Potential implications for breast cancer bone metastasis , 2014, Bone.
[50] Sung-Bae Kim,et al. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01) , 2010, Breast Cancer Research and Treatment.
[51] D. Cameron,et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. , 2014, The Lancet. Oncology.
[52] I. Holen,et al. A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts , 2012, Journal of bone oncology.
[53] F. Bauss,et al. Site‐specific human breast cancer (MDA‐MB‐231) metastases in nude rats: Model characterisation and in vivo effects of ibandronate on tumour growth , 2003, International journal of cancer.
[54] M. Gnant,et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[55] J. A. Bennett,et al. Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial , 2011, Breast Cancer Research and Treatment.
[56] L. Ford,et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.
[57] P. Goss,et al. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women , 2007, Breast Cancer Research.
[58] C. Blomqvist,et al. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. , 2004, Journal of Clinical Oncology.
[59] Janet E Brown,et al. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer , 2010 .
[60] W. Gregory,et al. Breast-cancer adjuvant therapy with zoledronic acid. , 2011, The New England journal of medicine.
[61] J. Purnell,et al. Effects of a structured weight-bearing exercise program on bone metabolism among breast cancer survivors: a feasibility trial. , 2010, Clinical breast cancer.
[62] T. Powles,et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. , 1998, Journal of the National Cancer Institute.
[63] P. Delmas,et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] F. Montemurro,et al. Adjuvant ovarian suppression in premenopausal breast cancer. , 2015, The New England journal of medicine.
[65] C. Shapiro. Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast Cancer , 2009 .
[66] R. Brook,et al. Consensus methods: characteristics and guidelines for use. , 1984, American journal of public health.
[67] M. Intorcia,et al. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates , 2011, Osteoporosis International.
[68] S. Cawthorn,et al. Reversal of skeletal effects of endocrine treatments in the intergroup exemestane study. , 2009 .
[69] C. Blomqvist,et al. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. , 2001, European journal of cancer.
[70] F. Saad,et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[71] R. Kimmig,et al. Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study. , 2011, Anticancer research.
[72] M. Beckmann,et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[73] W. Gregory,et al. Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: Results of a meta-analysis. , 2012 .
[74] Jacques P. Brown,et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women , 2007, Osteoporosis International.
[75] C. Fisher. Metastasis , 1989, Ciba Foundation symposium.
[76] M. Gnant,et al. Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? , 2012, Cancer treatment reviews.
[77] P. Dong,et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. , 2009, The New England journal of medicine.
[78] M. Seibel,et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. , 2007, Bone.
[79] Vered Stearns,et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.